The Colorectal Therapies HTC has been successful in its bid to host a new NIHR Medical Technology and In Vitro Diagnostic Co-operative (NIHR MIC).
In January 2018, the HTC will become the NIHR Surgical MedTech Co-operative - one of a national network of 11 NIHR MICs announced as part the government’s Life Science Industrial Strategy this week.
The NIHR Surgical MedTech Co-operative will provide support for companies developing new medical devices for use across colorectal, vascular and hepatopancreaticobiliary diseases – areas of surgery which all face substantial challenges, and which will benefit from technological innovation.
Expertise available to industrial partners will include engineering support for medical device and robotic technology development, nanotechnology development and biosensor development, support for designing and running clinical evaluations and health economic assessments of innovative devices.
“Since its inception in 2013, the HTC has built up a national network of partners, drawn from academia, clinicians, industry, and patients and public, to identify challenges in surgical healthcare and devise solutions to overcome them. Winning the bid to become the NIHR Surgical MedTech Co-operative provides us with a great opportunity to build on this success,” says HTC Clinical Director, Professor David Jayne, who will now lead the new programme.
Vee Mapunde, Programme Manager of the Colorectal Therapies Healthcare Technologies Cooperative, will continue her role for the new initiative. She adds: “Surgery plays a central role in the management of many medical conditions and whilst there is no shortage of surgical innovations only a few make it to clinical practice. Early clinical involvement has been identified as the biggest obstacle to successful translation and by working with our key stakeholders, the NIHR Surgical MedTech Cooperative will address many of the important unmet surgical needs and provide the expertise and resource needed to translate new technologies into patient benefit.”